Advertisement
Canada markets open in 57 minutes
  • S&P/TSX

    22,107.08
    +194.56 (+0.89%)
     
  • S&P 500

    5,248.49
    +44.91 (+0.86%)
     
  • DOW

    39,760.08
    +477.75 (+1.22%)
     
  • CAD/USD

    0.7364
    -0.0008 (-0.11%)
     
  • CRUDE OIL

    82.62
    +1.27 (+1.56%)
     
  • Bitcoin CAD

    95,733.88
    +301.85 (+0.32%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,231.90
    +19.20 (+0.87%)
     
  • RUSSELL 2000

    2,114.35
    +44.19 (+2.13%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • NASDAQ futures

    18,500.75
    -3.00 (-0.02%)
     
  • VOLATILITY

    13.02
    +0.24 (+1.88%)
     
  • FTSE

    7,952.37
    +20.39 (+0.26%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • CAD/EUR

    0.6817
    +0.0012 (+0.18%)
     

Syros Pharmaceuticals Stock Appears To Be Possible Value Trap

- By GF Value

The stock of Syros Pharmaceuticals (NAS:SYRS, 30-year Financials) gives every indication of being possible value trap, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher. At its current price of $5.61 per share and the market cap of $347 million, Syros Pharmaceuticals stock is estimated to be possible value trap. GF Value for Syros Pharmaceuticals is shown in the chart below.


Syros Pharmaceuticals Stock Appears To Be Possible Value Trap
Syros Pharmaceuticals Stock Appears To Be Possible Value Trap

The reason we think that Syros Pharmaceuticals stock might be a value trap is because Syros Pharmaceuticals has an Altman Z-score of -0.36, which indicates that the financial condition of the company is in the distressed zone and implies a higher risk of bankruptcy. An Altman Z-score of above 2.99 would be better, indicating safe financial conditions. To learn more about how the Z-score measures the financial risk of the company, please go here.

ADVERTISEMENT

Link: These companies may deliever higher future returns at reduced risk.

Since investing in companies with low financial strength could result in permanent capital loss, investors must carefully review a company's financial strength before deciding whether to buy shares. Looking at the cash-to-debt ratio and interest coverage can give a good initial perspective on the company's financial strength. Syros Pharmaceuticals has a cash-to-debt ratio of 3.37, which ranks worse than 67% of the companies in Biotechnology industry. Based on this, GuruFocus ranks Syros Pharmaceuticals's financial strength as 4 out of 10, suggesting poor balance sheet. This is the debt and cash of Syros Pharmaceuticals over the past years:

Syros Pharmaceuticals Stock Appears To Be Possible Value Trap
Syros Pharmaceuticals Stock Appears To Be Possible Value Trap

It poses less risk to invest in profitable companies, especially those that have demonstrated consistent profitability over the long term. A company with high profit margins is also typically a safer investment than one with low profit margins. Syros Pharmaceuticals has been profitable 0 over the past 10 years. Over the past twelve months, the company had a revenue of $17.5 million and loss of $1.67 a share. Its operating margin is -489.67%, which ranks in the middle range of the companies in Biotechnology industry. Overall, GuruFocus ranks the profitability of Syros Pharmaceuticals at 3 out of 10, which indicates poor profitability. This is the revenue and net income of Syros Pharmaceuticals over the past years:

Syros Pharmaceuticals Stock Appears To Be Possible Value Trap
Syros Pharmaceuticals Stock Appears To Be Possible Value Trap

Growth is probably the most important factor in the valuation of a company. GuruFocus research has found that growth is closely correlated with the long term performance of a company's stock. The faster a company is growing, the more likely it is to be creating value for shareholders, especially if the growth is profitable. The 3-year average annual revenue growth rate of Syros Pharmaceuticals is 96.8%, which ranks better than 93% of the companies in Biotechnology industry. The 3-year average EBITDA growth rate is 6.3%, which ranks in the middle range of the companies in Biotechnology industry.

Another way to evaluate a company's profitability is to compare its return on invested capital (ROIC) to its weighted cost of capital (WACC). Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business. The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. If the ROIC is higher than the WACC, it indicates that the company is creating value for shareholders. Over the past 12 months, Syros Pharmaceuticals's ROIC was -170.65, while its WACC came in at 13.64. The historical ROIC vs WACC comparison of Syros Pharmaceuticals is shown below:

Syros Pharmaceuticals Stock Appears To Be Possible Value Trap
Syros Pharmaceuticals Stock Appears To Be Possible Value Trap

To conclude, The stock of Syros Pharmaceuticals (NAS:SYRS, 30-year Financials) is estimated to be possible value trap. The company's financial condition is poor and its profitability is poor. Its growth ranks in the middle range of the companies in Biotechnology industry. To learn more about Syros Pharmaceuticals stock, you can check out its 30-year Financials here.

To find out the high quality companies that may deliever above average returns, please check out GuruFocus High Quality Low Capex Screener.

This article first appeared on GuruFocus.